Clinical potential of microRNAs in pancreatic ductal adenocarcinoma
Related Experiment Video
Updated: May 28, 2026
An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
Colin W Steele1, Karin A Oien, Colin J McKay
1Beatson Institute for Cancer Research, Glasgow, UK.
Objectives:
Aggressive invasion and early metastases are characteristic features of pancreatic ductal adenocarcinoma (PDAC). More than 90% of patients have surgically nonresectable disease at presentation. Despite increasing knowledge of the genetics of this complex disease, systemic therapies, particularly gemcitabine, have modest clinical benefit and marginal survival advantage. MicroRNAs have been shown to have a role in oncogenesis, invasion, and metastases via epigenetic posttranscriptional gene regulation. Our objective was to discuss the clinical impact of microRNAs within PDAC.
Methods:
This review details the understanding of microRNAs to date and explores the clinical utility of microRNAs in PDAC.
Results:
Recent studies have focused on the impact of microRNA expression in PDAC, many of which have shown the diagnostic, predictive, and prognostic utility of microRNA profiling in PDAC identifying numerous potential targets including miR-21, miR-196a, and miR-217.
Conclusions:
MicroRNA stability in body fluid and tissue samples makes this area one of the most promising for earlier detection of PDAC. Indeed, microRNAs may in the future serve as a long-awaited screening tool for PDAC. Furthermore, microRNA expression profiling in PDAC may be incorporated into modern treatment algorithms to enhance therapeutic management. Equally as exciting is the potential for novel therapeutics directed against these important disease mediators.
Insights
MicroRNAs show promise for early pancreatic cancer detection and improved treatment. Their stability in samples offers a potential new screening tool for pancreatic ductal adenocarcinoma (PDAC).
Area of Science:
- Oncology
- Molecular Biology
- Epigenetics
Background:
- Pancreatic ductal adenocarcinoma (PDAC) is characterized by aggressive invasion and early metastasis.
- Most patients present with surgically unresectable disease, and current therapies offer limited benefit.
- MicroRNAs regulate gene expression and play a role in cancer development, invasion, and metastasis.
Purpose of the Study:
- To review the current understanding of microRNAs in PDAC.
- To explore the clinical impact and utility of microRNAs in pancreatic cancer.
Main Methods:
- Literature review of microRNA research in PDAC.
- Analysis of studies on microRNA expression profiling and its diagnostic, predictive, and prognostic value.
Main Results:
- MicroRNA profiling in PDAC has demonstrated diagnostic, predictive, and prognostic utility.
- Specific microRNAs such as miR-21, miR-196a, and miR-217 have been identified as potential targets.
- MicroRNA stability in biological samples is a key factor for their clinical application.
Conclusions:
- MicroRNAs offer a promising avenue for earlier PDAC detection and may serve as a screening tool.
- MicroRNA expression profiling can enhance therapeutic management strategies for PDAC.
- Novel therapeutics targeting microRNAs hold potential for treating pancreatic cancer.
Related Concept Videos
01:22MicroRNAs
01:22MicroRNAs